Vaccinex stock: Vaccinex reports 38-patient melanoma findings. Results inform Vaccinex stock

Published on 10/24/2026 at 00:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 2.10 million in fiscal year 2025. The next report date listed for Vaccinex stock is November 16, 2026.

Clinical evidence and reporting dates

On October 7, 2026, Vaccinex published melanoma findings from a 38-patient pilot study.
Fiscal-year revenue increased from USD 0.60 million in 2024 to USD 2.10 million in 2025, a 250.00 percent rise.
TradingView lists November 16, 2026 as the next earnings date.

VCNX, US9186403013, Illustration mit AI erstellt.

Vaccinex (ISIN US9186403013) reported findings from a 38-patient melanoma study on October 7, 2026, as Yahoo Finance carried the release. The pilot study examined pepinemab with nivolumab and or ipilimumab before surgery, giving Vaccinex a clinical data point while keeping the evidence focused on tumor biology rather than efficacy proof.

What did the melanoma study show?

The predefined biomarker endpoint was met, and the researchers linked pepinemab-containing regimens with changes in the tumor immune environment. The study also associated a greater abundance of mature lymphoid aggregates with longer recurrence-free survival, although its 38-patient design was intended to examine biological effects rather than establish clinical benefit.

Patients received two doses before planned surgery, according to Yahoo Finance. The treatment did not prevent or postpone curative-intent resection, and the release reported zero grade 4 or 5 adverse events during treatment before or after surgery. For investors, the key distinction is between a biological signal and a proven clinical outcome.

How large is the financial base?

Vaccinex remained a small clinical-stage biotechnology company, with pepinemab as its lead candidate for neurodegenerative disease and oncology applications, according to the company's investor overview at Vaccinex. Revenue increased from USD 0.60 million in fiscal year 2024 to USD 2.10 million in fiscal year 2025, a 250.00 percent increase. The 2024 figure appears in Investing.com, while the 2025 figure is listed by TradingView.

When is the next report date?

TradingView lists November 16, 2026 as the next earnings date for Vaccinex. That date gives the market a defined point for reviewing cash use, development progress and any update to the pepinemab program.

Clinical evidence sets the next test

The October 7 publication strengthens the scientific rationale around pepinemab, but the study's small size leaves larger clinical testing as the next evidentiary step. The upcoming November reporting date may therefore matter less for revenue than for financing, trial execution and the company's ability to advance its lead program.